Challenge Your Exam Readiness With Our Free AOCNP Practice Questions

Eligibility for germline testing is driven by tumor features and age—not solely family history. Triple-negative breast cancer diagnosed at age ≤60 meets criteria for germline testing (e.g., BRCA1/2 and other susceptibility genes). Identifying a pathogenic variant informs surgical planning (risk-reducing options), systemic therapy choices (e.g., PARP inhibitors), radiation considerations, and cascade testing for relatives. Tumor-only sequencing (Option D) may detect somatic variants and occasionally suggest germline findings, but it is not a substitute for dedicated germline testing with pre- and post-test counseling. Waiting for ovarian cancer (Option B) misses timely, impactful information. Declining testing due to a negative family history (Option A) ignores the limited sensitivity of pedigree screening, small families, and de novo variants. The APRN coordinates rapid referral to genetics, discusses implications of results, turnaround times relative to treatment decisions, and psychosocial aspects (insurance, disclosure). Document informed consent, manage patient expectations regarding variants of uncertain significance, and plan for modification of therapy based on actionable findings.